⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MAIA News
MAIA Biotechnology, Inc.
MAIA Biotechnology Announces $1.51 Million Private Placement
globenewswire.com
MAIA
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
globenewswire.com
MAIA
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
globenewswire.com
MAIA
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential
globenewswire.com
MAIA
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
globenewswire.com
MAIA
MRK
MAIA Biotechnology Announces Open Market Purchases by CEO and Directors
globenewswire.com
MAIA
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
globenewswire.com
MAIA
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation
globenewswire.com
MAIA
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
globenewswire.com
MAIA
MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
globenewswire.com
MAIA